What are the best peptides for muscle growth?

In the research discussion, the two most-cited 'muscle' peptides are the GH-secretagogue pair CJC-1295 (a long-acting GHRH analog) and Ipamorelin (a selective GH-releasing pentapeptide). But 'best for muscle growth' overstates the evidence: these are studied for raising growth hormone and IGF-1 (Teichman et al., J Clin Endocrinol Metab 2006; Raun et al., Eur J Endocrinol 1998), not for building muscle. There is no controlled human trial showing either increases lean mass in healthy adults. They are research-use-only compounds and this is a research reference, not medical advice.

Do CJC-1295 and ipamorelin actually build muscle?

The honest answer is that this is not proven in humans. What is documented is that CJC-1295 raises GH and IGF-1 for several days after a dose, and ipamorelin selectively releases GH. The 'builds muscle' idea is an inference from the GH→IGF-1→muscle-protein-synthesis pathway (IGF-1 activates PI3K-AKT-mTOR to raise protein synthesis). That pathway is real, but no controlled trial has shown these specific peptides increase lean mass or strength in healthy people. Elevating IGF-1 is not the same as demonstrating hypertrophy.

Why are CJC-1295 and ipamorelin used together?

Because they act on two different receptors. CJC-1295 works through the GHRH receptor and ipamorelin through the GH-secretagogue (ghrelin) receptor, and co-activating both pathways produces a larger, supra-additive GH pulse than either alone — Hataya et al. (J Clin Endocrinol Metab 2001;86:4552-4555) showed low-dose ghrelin plus GHRH released GH synergistically in humans. Ipamorelin is favoured over older GHRPs because it does this without a significant cortisol or prolactin rise. This is a mechanism for greater GH release — still not a demonstration of greater muscle.

Are these peptides steroids or SARMs?

No. CJC-1295 and ipamorelin are GH secretagogues — they signal your own pituitary to release growth hormone in pulses, rather than being synthetic androgens (steroids) or selective androgen receptor modulators (SARMs). They are not FDA-approved for human use and Titan sells them strictly as research-use-only reagents, with no human-use, dosing, or efficacy claims. Anyone marketing them as a legal steroid alternative is making a claim the regulatory status and evidence do not support.

How do I know a CJC-1295 + Ipamorelin vial is the real material?

Both are sequence-defined peptides and this SKU is a blend, so a truncated sequence or an off-ratio blend can pass a simple HPLC purity number while being the wrong material — meaning none of the cited research transfers to that vial. Genuine identity is confirmed by mass spectrometry against the expected sequences, matched to the specific lot, not by purity alone. Titan provides lot-matched, in-house release documentation (HPLC vs a ≥99% internal target + ESI-MS identity) on request. We do not claim a third-party certificate; the verifiable edge is a real, lot-matched in-house release sheet.

peptides for muscle growth · what the research studies · research use only

Best peptides for muscle growth: the honest version of what the research shows.

Search 'best peptides for muscle growth' and the same pair keeps coming up: CJC-1295 and Ipamorelin — the 'GH-secretagogue' peptides. Here is the honest headline before anything else: these compounds are studied for raising growth hormone (GH) and IGF-1, not for building muscle in humans. There is no controlled human trial showing that CJC-1295 or ipamorelin increases lean mass or muscle hypertrophy in healthy people. What the research does establish is the pharmacology: CJC-1295 is a long-acting analog of GH-releasing hormone (GHRH) that produced dose-dependent, multi-day elevations in GH and IGF-1 in healthy adults (Teichman et al., J Clin Endocrinol Metab 2006;91:799-805 — GH up 2- to 10-fold for ~6 days, IGF-1 up 1.5- to 3-fold for ~9-11 days after a single dose). Ipamorelin is the first selective GH secretagogue, a pentapeptide that releases GH without spiking cortisol, ACTH or prolactin (Raun et al., Eur J Endocrinol 1998;139:552-561). The muscle-growth story is inferred from the GH→IGF-1→muscle-protein-synthesis axis — real biology, but the leap from 'raises IGF-1' to 'builds muscle in a healthy person' is exactly that: a leap, not a proven result. This page reproduces published research as a reference. It is research-use-only and not medical, dosing, or human-use advice. Of the muscle-adjacent research peptides, the single GH-secretagogue format Titan actually stocks is the pre-blended CJC-1295 + Ipamorelin vial.

CJC-1295 + Ipamorelin — $119.99 All research peptides

CJC-1295 — the long-acting GHRH analog

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). In the key human study, Teichman, Ferris, Jiang and colleagues (J Clin Endocrinol Metab 2006;91:799-805) gave single subcutaneous doses to healthy adults and reported dose-dependent GH increases of about 2- to 10-fold lasting roughly 6 days, and IGF-1 increases of about 1.5- to 3-fold lasting about 9-11 days, with an apparent half-life near 6-8 days. Note what that study measured: GH and IGF-1 blood levels and safety — not muscle mass. It is a pharmacodynamics result, not a body-composition result.

CJC-1295 + Ipamorelin research guide →

Ipamorelin — the first selective GH secretagogue

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts on the GH-secretagogue (ghrelin) receptor. Raun, Hansen, Johansen and colleagues (Eur J Endocrinol 1998;139:552-561) showed it releases GH with potency similar to GHRP-6 but — unlike GHRP-6 and GHRP-2 — without significantly raising ACTH, cortisol or prolactin, even at doses well above the GH-active level. That selectivity is why it is paired with CJC-1295 in research literature. Again: this is a GH-release finding, not a demonstration of muscle growth.

CJC-1295 + Ipamorelin half-life →

Why the two are studied together (two receptors)

The rationale for the pair is that they act on different receptors — CJC-1295 on the GHRH receptor, ipamorelin on the GH-secretagogue (ghrelin) receptor. In humans, co-activating these two pathways produces a larger, supra-additive GH pulse than either alone: Hataya, Akamizu and colleagues (J Clin Endocrinol Metab 2001;86:4552-4555) showed a low dose of ghrelin (a GHS-receptor agonist) released GH synergistically when combined with GHRH. That is the mechanistic basis for the 'CJC + Ipa' stack — greater GH release, which is still not the same claim as greater muscle.

CJC-1295 + Ipamorelin dosage reference →

The IGF-1 → muscle link (where the inference comes from)

The whole 'muscle' association runs through IGF-1. GH drives IGF-1 production, and IGF-1 is a central mediator of muscle protein synthesis — it activates the PI3K-AKT-mTOR pathway to increase translation and reduce proteolysis (reviewed in Yoshida & Delafontaine, Cells 2020;9:1970, 'Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy'; and Velloso, Br J Pharmacol 2008;154:557-568, 'Regulation of muscle mass by growth hormone and IGF-I'). Real pathway biology — but the studies establishing it are not studies of these peptides in healthy people building muscle. The chain 'peptide raises IGF-1, IGF-1 can drive hypertrophy' is plausible mechanism, not proof of outcome.

MK-677 vs CJC-1295 →

These are not steroids or SARMs — and the human evidence is the gap

GH secretagogues work by nudging your own pituitary to release GH in pulses; they are not anabolic steroids and not SARMs, and they are not approved for human use. The honest limitation is the human evidence: there is no controlled trial showing CJC-1295 or ipamorelin increases lean mass or strength in healthy adults. GH/IGF-1 elevation is documented; muscle-growth benefit is inferred and largely untested by RCT. Treat any confident 'best peptide to build muscle' claim as marketing that has run past the data.

Best peptides for recovery →

For a blended GH-secretagogue vial, identity is the real variable

CJC-1295 and ipamorelin are both sequence-defined peptides, and this SKU is a two-peptide blend — so a truncated or mis-synthesised chain, or a wrong blend ratio, can pass a bare purity number while being the wrong material, in which case none of the research above transfers to that vial. That is why identity by mass spectrometry, matched to the specific lot, matters more than a headline purity percentage. Titan supplies the CJC-1295 + Ipamorelin blend with lot-matched, in-house release documentation (HPLC purity vs a ≥99% internal target + ESI-MS identity) available on request. No third-party certificate is claimed; the honest edge is a real, lot-matched in-house release sheet.

Lot COA checklist →

The detail, in plain terms

Peptides-for-muscle-growth research, at a glance.

Points below summarise the published research on the most-discussed 'muscle' peptides, reproduced as a research reference. The documented findings are GH and IGF-1 elevation — not muscle growth in humans. There is no controlled human trial establishing CJC-1295 or ipamorelin as a proven muscle-building agent. Treat this as 'raises GH/IGF-1 in studies,' not 'proven to build muscle.' Research use only.

Most-discussed 'muscle' peptides: The GH-secretagogue pair: CJC-1295 (long-acting GHRH analog) and Ipamorelin (selective GH-releasing pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2).
CJC-1295 human finding: Single SC dose in healthy adults raised GH ~2- to 10-fold (~6 days) and IGF-1 ~1.5- to 3-fold (~9-11 days); half-life ~6-8 days — Teichman et al., J Clin Endocrinol Metab 2006;91:799-805. GH/IGF-1 data, not muscle data.
Ipamorelin finding: Selective GH release with potency like GHRP-6 but without significant ACTH/cortisol/prolactin rise — Raun et al., Eur J Endocrinol 1998;139:552-561. A GH-release result.
Why the pair (two receptors): GHRH-receptor (CJC-1295) + GH-secretagogue/ghrelin-receptor (ipamorelin) co-activation gives a supra-additive GH pulse — Hataya et al., J Clin Endocrinol Metab 2001;86:4552-4555 (ghrelin + GHRH synergy in humans).
The IGF-1 → muscle pathway: IGF-1 mediates GH's anabolic signal via PI3K-AKT-mTOR to raise protein synthesis — Yoshida & Delafontaine, Cells 2020;9:1970; Velloso, Br J Pharmacol 2008;154:557-568. Pathway biology, not a peptide muscle trial.
Human muscle-growth evidence: None specific to these peptides: no controlled trial shows CJC-1295 or ipamorelin increases lean mass or strength in healthy adults. The muscle benefit is inferred, not proven.
What these are NOT: Not anabolic steroids, not SARMs, not FDA-approved for human use. Research-use-only compounds; Titan makes no human-use, dosing or efficacy claim.
Identity check: Sequence-defined blend; identity by mass spec matched to the lot is the real check, not a bare purity %. Titan: lot-matched in-house HPLC + ESI-MS release sheet on request.

Questions researchers ask

Before you order.

What are the best peptides for muscle growth?: In the research discussion, the two most-cited 'muscle' peptides are the GH-secretagogue pair CJC-1295 (a long-acting GHRH analog) and Ipamorelin (a selective GH-releasing pentapeptide). But 'best for muscle growth' overstates the evidence: these are studied for raising growth hormone and IGF-1 (Teichman et al., J Clin Endocrinol Metab 2006; Raun et al., Eur J Endocrinol 1998), not for building muscle. There is no controlled human trial showing either increases lean mass in healthy adults. They are research-use-only compounds and this is a research reference, not medical advice.
Do CJC-1295 and ipamorelin actually build muscle?: The honest answer is that this is not proven in humans. What is documented is that CJC-1295 raises GH and IGF-1 for several days after a dose, and ipamorelin selectively releases GH. The 'builds muscle' idea is an inference from the GH→IGF-1→muscle-protein-synthesis pathway (IGF-1 activates PI3K-AKT-mTOR to raise protein synthesis). That pathway is real, but no controlled trial has shown these specific peptides increase lean mass or strength in healthy people. Elevating IGF-1 is not the same as demonstrating hypertrophy.
Why are CJC-1295 and ipamorelin used together?: Because they act on two different receptors. CJC-1295 works through the GHRH receptor and ipamorelin through the GH-secretagogue (ghrelin) receptor, and co-activating both pathways produces a larger, supra-additive GH pulse than either alone — Hataya et al. (J Clin Endocrinol Metab 2001;86:4552-4555) showed low-dose ghrelin plus GHRH released GH synergistically in humans. Ipamorelin is favoured over older GHRPs because it does this without a significant cortisol or prolactin rise. This is a mechanism for greater GH release — still not a demonstration of greater muscle.
Are these peptides steroids or SARMs?: No. CJC-1295 and ipamorelin are GH secretagogues — they signal your own pituitary to release growth hormone in pulses, rather than being synthetic androgens (steroids) or selective androgen receptor modulators (SARMs). They are not FDA-approved for human use and Titan sells them strictly as research-use-only reagents, with no human-use, dosing, or efficacy claims. Anyone marketing them as a legal steroid alternative is making a claim the regulatory status and evidence do not support.
How do I know a CJC-1295 + Ipamorelin vial is the real material?: Both are sequence-defined peptides and this SKU is a blend, so a truncated sequence or an off-ratio blend can pass a simple HPLC purity number while being the wrong material — meaning none of the cited research transfers to that vial. Genuine identity is confirmed by mass spectrometry against the expected sequences, matched to the specific lot, not by purity alone. Titan provides lot-matched, in-house release documentation (HPLC vs a ≥99% internal target + ESI-MS identity) on request. We do not claim a third-party certificate; the verifiable edge is a real, lot-matched in-house release sheet.